Recently, a modular plant project, contracted by Pharmadule Morimatsu AB for a global biotechnology company, has successfully completed its delivery in the U.S. The undertaking encompasses over 240 modules, comprising a workshop for producing stock solutions as well as a workshop for preparing and packaging goods, spread over an aggregate floor area of around 12,000 square meters. This allows for the seamless fusion of factory and process modules. Upon finalizing the construction of this production facility, there is an anticipated increase in the production capacity of biological agents to up to 16,000 liters. This will expedite the conversion of customers' innovative and distinct accomplishments.
Pharmadule Morimatsu AB held responsibility for various project aspects including the basic design, detailed design, factory fabrication, shipping, and on-site installation support. Within a span of 10 months, Pharmadule Morimatsu AB has effectively executed a comprehensive end-to-end solution encompassing design, procurement, manufacturing, FAT factory test and inspection, packaging, and transportation. This remarkable performance has been made possible owing to its proficient engineering management and design expertise, coupled with the adept supply chain deployment and top-notch manufacturing capabilities.
Despite the obstacles posed by the COVID-19 pandemic lockdown and disparate geographical locations of the project participants across differing time zones worldwide, the team at Pharmadule Morimatsu AB effectively navigated these challenges to successfully complete the project. Pharmadule Morimatsu AB established and sustained effective and frequent communication with the client's team, U.S. drawing reviewer, and statutory third-party inspection company, leveraging the benefits of an off-site modular plant construction approach to achieve a remarkable 80% factory fabrication, as well as high levels of integration across cleanroom, process equipment, ducting, ventilation, electrical, BMS & EMS, fire alarm, security, and other systems. This approach lessened the on-site workload, resulting in a significant reduction in the overall project construction cycle duration and yielding a notable example of a fast-delivery modular plant, realized in partnership with the client and collaborators.
Ensure high-quality standards while driving innovation. With Pharmadule Morimatsu AB's impressive track record in modular whole-plant delivery and a pressing need from the clients to consistently improve the delivery process, Pharmadule Morimatsu AB is committed to expanding its services, assisting clients in constructing overseas plants, expediting global layout, diversifying the supply chain, and ensuring improved outcomes for patients worldwide.
About Pharmadule Morimatsu AB
Pharmadule, a globally recognized leader in modular plant and solutions provision, has proudly completed 80 production facilities within the pharmaceutical and biopharmaceutical industries, along with over 300 successful engineering design and validation solutions since its establishment in 1986. With extensive experience in international project delivery and proper understanding of regulatory requirements in different regions, Pharmadule continues to provide a range of engineering and solutions to pharmaceutical and biopharmaceutical clients worldwide. After becoming a member of Morimatsu Group in 2011, Pharmadule Morimatsu AB perfectly integrates modular plants with process thanks to the strong combination, allowing the company to provide clients with higher-quality and faster turnkey solutions. Pharmadule Morimatsu AB has been selected by globally recognized pharmaceutical clients including Eli Lily, Merck, Baxter, GSK, Genentech, AZ and Lonza, to facilitate quicker and more efficient patient treatment plans.
About Morimatsu Life Science
Morimatsu Life Science is the sanitary business segment of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), covering industries such as pharmaceuticals, biopharmaceuticals, FMCG, cosmetic and electronic chemicals, and mainly includes Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and other companies and their affiliates, focusing on the R&D, manufacturing and sales of products in related fields.
Morimatsu, founded in Japan and taken root in China, has developed into a multi-national company that embraces globalization, masters core technology, and gains rich experience from project implementation in diverse fields including core equipment, process systems, and engineering solutions. Starting from its advanced manufacturing base in China, Morimatsu International has opened subsidiaries or plants in Sweden, the United States, India, Italy, Malaysia and Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by virtue of its global footprint of efficient and professional team.
The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of “predicted”, “believed”, “forecast”, “planned” and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our company undertakes no obligation to constantly revise such predicted statements.
Forward-looking statements are based on our company management’s current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guaranties of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.